suMMARY The effects of intracoronary and intravenous infusions of amninone were studied to distinguish the drug's direct cardiac actions from its peripheral vascular and neuroendocrine properties. Intracoronary infusions of amrinone were found to have no haemodynamic effect other than producing a slight reduction in the left ventricular ejection fraction and some suggestion of coronary vasodilatation in patients with impaired left ventricular function. They did not improve contractility, cardiac output, or filling pressures and had no significant effect on myocardial metabolism, although therapeutic concentrations of the drug were detected in coronary sinus blood. Intravenously administered amrinone reduced filling pressures and improved the cardiac index in all patients, but haemodynamic improvements were most pronounced in the patients with the worst cardiac function. These changes were accompanied by improvements in the indices of contractility only in patients in whom alterations in concentrations of free fatty acid, glycerol, and glucose suggested peripheral catecholamine release. In the patients with the best basal cardiac function intravenously administered amrinone produced a reduction in myocardial work and evidence of myocardial ischaemia, as a result of excessive reduction of coronary perfusion pressure and increased heart rate, without any appreciable increase in cardiac index.
suMMARY The effects of intracoronary and intravenous infusions of amninone were studied to distinguish the drug's direct cardiac actions from its peripheral vascular and neuroendocrine properties. Intracoronary infusions of amrinone were found to have no haemodynamic effect other than producing a slight reduction in the left ventricular ejection fraction and some suggestion of coronary vasodilatation in patients with impaired left ventricular function. They did not improve contractility, cardiac output, or filling pressures and had no significant effect on myocardial metabolism, although therapeutic concentrations of the drug were detected in coronary sinus blood. Intravenously administered amrinone reduced filling pressures and improved the cardiac index in all patients, but haemodynamic improvements were most pronounced in the patients with the worst cardiac function. These changes were accompanied by improvements in the indices of contractility only in patients in whom alterations in concentrations of free fatty acid, glycerol, and glucose suggested peripheral catecholamine release. In the patients with the best basal cardiac function intravenously administered amrinone produced a reduction in myocardial work and evidence of myocardial ischaemia, as a result of excessive reduction of coronary perfusion pressure and increased heart rate, without any appreciable increase in cardiac index.
It is concluded that, at the concentrations of the drug that can be achieved in man without adverse effects, amrinone has no direct positive inotropic effect. Haemodynamic changes are predominantly the result of vasodilatation, although catecholamines may be released in some patients.
Amrinone (Inocor; Winthrop-Breon, USA) is the prototype of a group of new drugs that are currently being investigated for use in the treatment of patients with heart failure. Amrinone acutely lowers cardiac filling pressures and improves cardiac output' without increasing myocardial oxygen consumption.2 3 These effects have been largely attributed to the direct positive inotropic action that has been shown with the drug in normal animal myocardium.4 s Relatively less attention has been paid to the direct vasodilator properties of amrinone.5 6 In patients with cardiac failure initial small studies showed an improvement in a contractility index
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Acceptd for publicaion 3 January 1984 (maximum rate of rise of left ventricular pressure (dP/dt max)) after intravenous administration of amrinone.7-9 These studies contained flaws in experimental design, which we have discussed previously,10-12 not least of these being the absence of any attempt to look for a dose response relation between the amount of amrinone administered and changes in contractility. Subsequent studies that sought a doseresponse relation and contained larger numbers of observations than the earlier reports found no evidence of a positive inotropic effect in patients.3 10 13 Moreover, two of these subsequent studies compared the effects of amrinone with those of other agents commonly used in the treatment of cardiac failure.
One study compared amrinone with dobutamine,13 which possesses both positive inotropic and vasodilator properties. The authors showed no change in contractility after amrinone but an increase (partially Wilmshurst, Thompson, Juul, Dittrich, Dawson, Walker, Jenkins, Coltart, Webb-Peploe heart rate related) with dobutamine; both drugs also produced changes in haemodynamics attributable to vasodilatation. In the other study amrinone was compared with a pure vasodilator, nitroprusside.3 No difference between the effects of the two drugs was detected except for evidence that amrinone caused catecholamine release in some patients.
Because of this conflicting evidence and the difficulty of determining, by intravenous administration, the effect of drugs on the human myocardium in vivo we have investigated the effects of amrinone on the heart by administering it by intracoronary infusion.
Patients and methods
We studied eight men without significant coronary disease. Seven, aged 28-52 (mean 41) years, had dilated cardiomyopathy; of them, three gave a history of high alcohol intake. Six were in sinus rhythm and one in atrial fibrillation. All were receiving diuretics, six digoxin, and one each amiodarone, warfarin, and indomethacin. In addition, we studied a man aged 41 who gave a history of angina despite "normal coronary arteries and good left ventricular function" diagnosed at another hospital. He had been referred for investigation of the effect of atrial pacing on myocardial lactate extraction. He was receiving atenolol (100 mg daily) at the time of his investigation and had never been in cardiac failure. (Careful review of coronary angiograms after the trial showed that three patients with poor cardiac function had isolated-noncritical coronary narrowings (<50Yo), which were thought to be insufficient in number or site to account for their global cardiac dysfunction. The Cardiac output was measured by dye dilution'0 and coronary sinus flow by thermodilution,'4 as previously described. Pressures were measured with reference to the sternal angle as zero. Pressure, micromanometer, and thermistor signals were displayed on a Cambridge 12 channel recorder, stored on magnetic tape, and processed by computer. Indices of contractility, including dP/dt max, dP/dt max divided by developed pressure (dP/dt max/P),'5 the peak measured shortening velocity of the contractile element ((dP/dt/P) max),16 and the product of the series elastic stiffness constant and the velocity of contractile shortening at zero load (KV max),'7 were derived by on line computer processing of the pressure signal.'0
The plasma concentrations of amrinone and its metabolite, N-acetyl amrinone, were determined by high pressure liquid chromatography.'8 The oxygen content and concentrations of lactate, pyruvate, hydroxybutyrate, acetoacetate, glycerol, free fatty acid, and glucose in arterial and coronary sinus blood were determined as previously described.3 14 Myocardial oxygen consumption, left ventricular minute work, myocardial efficiency, and the myocardial extractions, extraction ratios, and oxygen extraction ratios of substrates were calculated using standard formulas. ' (SEM) . Statistical analysis for this group was by the paired t test. The initial control (basal) period was compared with the basal state before each intervention. The effects seen at all times after each intervention were compared with both the initial control period and the control period immediately before that intervention. In addition, the effects observed after intracoronary and intravenous infusion of amrinone were compared with the effects seen at the same intervals after intracoronary infusion of lactate.
The data on the two patients who received long intracoronary infusions were not amenable to statistical analysis, and the raw data are provided.
Further statistical analysis was by linear or log linear regression. Spearman's rank test was used to test for a non-parametric relation when one was sought but could not be detected using a simple algorithm. A p value of less than 0-05 was considered to be significant.
Results
PLASMA AMRINONE CONCENTRATIONS 5) . In contrast, in these six patients intravenous amrinone produced a significant (p<005) increase in heart rate at four minutes and a significant (p<0.05) reduction in left ventricular end diastolic pressure at all times after the intervention (Fig. 1) Samples of plasma for estimation of glucose concentration were unfortunately destroyed in two of the six patients who received the short intracoronary infusions. In the remainng four patients intracoronary infusions produced no detectable effect on the arterial or coronary sinus concentrations of glucose. A small effect could have been masked by the general tendency for the arterial glucose concentration to decline with time (presumably the result of fasting). In each patient, however, intravenous amrnone produced a rise in arterial and coronary sinus glucose concentration compared with the preceding estimation. The mean increase for both arterial and coronary sinus concentrations was 12 mmol/l. (Fig. 3) , pulmonary arterial and aortic pressures, left ventricular minute work, or systemic or pulmonary vascular resistances (Fig. 4) . In the patient with poor left ventricular function coronary sinus flow increased and coronary vascular resistance fell after intracoronary infusion of amrinone, but opposite changes were seen in the patient with good left ventricular function (Figs. 2 and 5) .
After receiving intravenous amrinone the patient with poor left ventricular function showed a transient rise in heart rate (maximum four minutes after the start of the infusion) and a later reduction in left ventricular filling pressure (Fig. 6) . Contractility indices were increased in this patient after the intravenous dose of amrinone, although no improvement in contractility had been seen during the intracoronary amrinone infusion. Changes in other haemodynamic indices, for example, heart rate, blood pressures, and flows-after intravenous amrinone in this patient, however, were comparable with those observed after intravenous amrinone in the six patients who received short intracoronary infusions (Figs. 2, 3, and 4) .
The responses seen after intravenous amrinone in the seven patients with poor left ventricular function differed a little from those observed in the patient with good left ventricular function. In this patient a reduction in left ventricular pressures also occurred, but the decrease in left ventricular systolic pressure was considerable (Fig. 7) . This was accompanied by a large increase in heart rate and contractility indices (Fig. 7) . The slight increase in cardiac index seen was due to the increase in heart rate, as left ventricular end diastolic volume and ejection fraction were unaltered (Fig. 3) . Pulmonary arterial and aortic pressures and systemic vascular resistance were considerably reduced after intravenous amrinone (Fig. 4) . In contrast to the changes in arteriocoronary sinus oxygen difference, left ventricular minute work, and efficiency observed after intravenous amrinone in the patients with poor left ventricular function, a slight reduction in minute work and no real alteration in efficiency or arteriocoronary sinus oxygen difference developed in the patient with good left ventricular function (Fig. 2) .
Metabolism
The metabolic effects of the long intracoronary infusions of amrinone and the lactate solution are difficult to determine as during the periods of sampling for metabolites both the subjects were receiving an * lar function (Table 4) . Increases in the arterial concentrations of glycerol, free fatty acid, glucose (Table  4) , hydroxybutyrate, and acetoacetate (not tabulated) were seen after intravenous amrinone in both patients. These changes were more pronounced in the patient with poor left ventricular function (glucose concentration being compared with the glucose concentration during the preceding intervention).
Inwrelations between variables measured
After intracoronary drug infusions we were unable to detect any relation between coronary sinus amrinone concentrations and haemodynamic or ;metabolic changes observed. Removal of the one or two patients with the lowest coronary sinus amrinone concentrations does not materially affect-mean values or the overana. Iysis of-data. Patients who received short or long intracoronary infusions received different total doses of the drugs by this route. They all subsequently received the same dose-of amninone (1-5 mg/kg) by the intravenous route. It was thus possible to analyse the haemodynamic, effects of intravenous amrinone in these eight patients combined. No relation was found between alterations in contractility and plasma concentrations of amiiinnone or N-acetyl amrnone. As in a previous study3 we sought a relation between alterations in haemodynamics and metabolic changes after intravenous amnrinone. The percentage increase in arterial free fatty acid concentration was linearly related to percentage increase in dP/dt max (y=7.83+0.38x, n=8, r=0.64), although the relation just failed to achieve significance (005<p<0-1).
An inverse relation existed between control left ventricular ejection fraction (%) and percentage increase in ejection fraction after intravenous amrinone (y=96.1-164x, n=8, r=0-714, p<0.05). In fact, a relation existed between a number of baseline (control) haemodynamic variables and the response to intravenous amnnone, although not to intracoronary amnnone.
We arbitrarily divided the patients into two groups of four; those with a noised left ventricular end diastolic volume >200 (range 209-241, mean 222) ml/m2 and those with a volume index <200 (range 112-183, mean 148) m/m2. Those 
Effects of intracoronary and intravenous amrinone infusions Hg/mi/M2), and lower left ventricular minute work vascular effects and systemic alterations of autonomic (1. 17-3*51 v 5-64-9-66 kg m/min) as well as generally or neuroendocrine activity from masking the cardiac lower efficiency (2-1-28.6, mean 10-9 v 8-8-35-1, effects of amrinone. These cardiac properties could mean 23.7%), cardiac indices (1.1-2*0, mean 1-6 include effects on coronary vessels, cardiac nerves, v l-8-32, mean 2*6 l/minim2), and ejection fractions and myocardial neurotransmitter potentiation, as well , mean 17 v 21-52, mean 39%). The two groups as direct effects on myocardial cells themselves. had similar resting heart rates, arteriocoronary sinus Intracoronary administration of any drug solution oxygen differences, coronary sinus flow rates, will have effects that are due to partial replacement of myocardial oxygen consumptions, and lactate extrac-coronary perfusing blood by nutrient poor, nontions. After intravenous amrinone filling pressures fell oxygenated solvent as well as those effects due to the by similar amounts in each group, but aortic pressure pharmacological properties of the drug itself. Consefell less in the group with the larger left ventricular quendy, it was necessary to investigate the effect of volumes (5 v 22 mm Hg). In the patients with the the solvent (lactate solution) itself in each patient larger ventricular volumes heart rate was unchanged studied. To prevent an order effect the intracoronary after amrinone but rose in the other group (range infusions were administered in a randomised cross-11-24 (mean 16) beats/min). Cardiac index rose in over manner. The patients and the technicians perboth groups after intravenous amrinone, but this forming biochemical analysis were unaware of interincrease was greater in the group with the larger left vention order, and haemodynamic measurements ventricular volume in both absolute (0.9-2.2 (mean were made by computer. Thus, although the doctors 1-4) v 0'2-1 0 (mean 0-5) 1/min) and relative terms giving the drugs were aware of the order of adminis-(45-122% (mean 89%) v 8-56% (mean 23%)). Left tration of the infusions (which were different colours) ventricular minute work fell after intravenous selection and biased interpretation of data were preamrinone in three of the group with the smaller left vented. This technique contrasts appreciably with ventricular volumes, and efficiency was reduced in earlier "titration" studies of the haemodynamic two, but both variables were improved in each of the effects of amrinone, in which peak effects and prefour patients with larger left ventricular volumes. In determined haemodynamic end points were emeach of the patients with smaller left ventricles, but ployed.79 Such studies cannot be used to argue that a not in the other group, the left ventricular end systolic drug possesses a particular effect, although the magpressure/volume index rose appreciably after nitude and time course of that effect can be assessed, amrinone. This change, however, was accompanied provided that the effect has already been adequately by a large increase in heart rate in each patient and shown to be present. was not accompanied by consistent alterations in presWe initially investigated the effect of short sure derived contractility indices.
intracoronary 21 In chronic cardiac failure in myocardium trations coronary sinus blood was sampled during from animals23 and man6 the direct positive inotropic the infusions. We also continued observation of effects of amrinone disappear. Even in normal haemodynamics after the intracoronary infusion in myocardium the concentrations of amrinone required case late changes occurred. to produce a direct positive inotropic effect are conWe administered the drug into the left coronary siderably higher than those that can be obtained dur-artery alone, aware that our failure to administer the ing long term oral treatment24 -26 because of common, drug also into the right coronary artery might produce severe, and dose related adverse effects.25 27 28 a steal phenomenon or regional dyskinesia. We Amrinone also possesses powerful direct vasodilator thought, however, that it would not be justified to properties in animal and human vessels5 629 and may cannulate both coronary ostia. The rate of drug infualso cause systemic catecholamine release in some sion was 0*5 mg/min, which we had estimated from cases by mechanisms independent of reflex changes mean coronary flows, would produce concentrations resulting from vasodilatation.3
.---of drug,in coronary sinus blood in the range of those This study is an attempt to prevent these peripheral detecte4.in<-peripheral blood during long term oral 503 group.bmj.com on June 22, 2017 -Published by http://heart.bmj.com/ Downloaded from treatment. (We have previously found an incidence of thrombocytopenia greater than 50% in patients receiving long term oral treatment when mean plasma amrinone concentration exceeds 2-5 g/ml,26 so we aimed to achieve coronary sinus concentrations of the drug that were lower than this.) We also predicted that unexpected adverse reactions to the intracoronary drug infusions would be unlikely to develop as the concentrations of drug achieved would be lower than those we found in the circulation during the initial five minutes after bolus adminstration of amrinone. These predictions proved accurate.
After this group of six preliminary experiments we intended to proceed to a series of further experiments in which the intracoronary infusions were considerably prolonged in case the occurrence of any inotropic effect of amrinone in vivo is delayed. It was our intention to investigate the effect of long infusions in at least six patients with dilated cardiomyopathy and in as many patients as might prove practical with normal coronary arteries and good left ventricular function who required investigation of myocardial lactate metabolism. We were unable to complete these experiments owing to the manufacturers' action.
In all patients, whether they received long or short intracoronary infusions, the effect of intravenous amrinone was also investigated. This was to confirm that these patients did not respond in an atypical manner to intravenous amrinone, which might for example have 
Effects of intracoronaty and intravenous amrinone infusions
In the present study we did find evidence to support the view that intravenous amrinone can produce systemic release of catecholamine. As in a previous study, we showed that, although contractility did not increase for the group as a whole after intravenous amrinone, changes in contractility in individual patients were related to metabolic alterations (increased free fatty acid, glycerol, and glucose concentrations), which suggests that they might be the result of catecholamine release.333 Indeed, in the present study the metabolic changes after 1*5 mg/kg intravenous amrinone were identical to those we have previously described in a similar group of patients after the same dose of the intravenous drug. 3 We also showed that improvements in left ventricular ejection fraction after intravenous amrinone were inversely related to control ejection fraction. The most beneficial changes in other haemodynamic and metabolic variables after the drug were found in the patients with the worst control haemodynamic values. These findings alone would suggest that the effects of intravenous amrinone in cardiac failure are predominately the result of altered loading, even if the effects of intracoronary infusion of amrinone had been less convincing.
Overall these findings agree with our previous observations that in patients with chronic heart failure improvements in haemodynamics after intravenous amrinone are the result of vasodilatation with no evidence of a direct positive inotropic effect.310 In such patients any improvement seen in contractility is likely to be due to the release of catecholamine. 3 In patients with milder degrees of heart failure an additional direct positive inotropic effect with high concentrations of amrinone cannot be entirely excluded. If present in such a patient, however, this effect coupled with the drug's powerful vasodilator properties might prove disadvantageous because the possible increase in heart rate coupled with excessive reductions in preload, coronary perfusion pressure, and myocardial efficiency may worsen myocardial ischaemia, without the benefit of an appreciable increase in cardiac index.
The intracoronary infusions confirmed that at concentrations of the drug likely to be achieved without adverse effects during long term oral treatment (that is, <2*5 Ag//ml26) amrinone has no positive inotropic effects in human myocardium whether it is from patients with heart failure or nearly normal subjects.
This study highlights the dangers of extrapolating from experiments using very high concentrations of drugs in isolated normal animal myocardium to lower (non-toxic) concentrations in the intact patient, without giving sufficient consideration to additional direct and indirect effects they may have on vessels and the neuroendocrine systems.
